Regencell Bioscience (NASDAQ:RGC) Shares Down 4.6% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price fell 4.6% during trading on Thursday . The stock traded as low as $6.03 and last traded at $6.02. Approximately 145,481 shares traded hands during mid-day trading, a decline of 51% from the average daily volume of 297,599 shares. The stock had previously closed at $6.31.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Wall Street Zen downgraded Regencell Bioscience from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Regencell Bioscience Stock Up 6.3%

The business’s fifty day moving average price is $5.74 and its 200 day moving average price is $18.25.

Institutional Trading of Regencell Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP acquired a new stake in Regencell Bioscience during the 4th quarter worth approximately $92,000. Amundi acquired a new position in shares of Regencell Bioscience in the first quarter valued at approximately $219,000. Vident Advisory LLC increased its holdings in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the period. Hudson Bay Capital Management LP purchased a new stake in shares of Regencell Bioscience during the fourth quarter worth approximately $275,000. Finally, Bank of America Corp DE raised its stake in shares of Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares during the last quarter. 0.13% of the stock is owned by hedge funds and other institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.